Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:2012:646191.
doi: 10.1155/2012/646191. Epub 2012 Jul 15.

Brachystemma calycinum D. Don Effectively Reduces the Locomotor Disability in Dogs with Naturally Occurring Osteoarthritis: A Randomized Placebo-Controlled Trial

Maxim Moreau  1 , Bertrand Lussier, Jean-Pierre Pelletier, Johanne Martel-Pelletier, Christian Bédard, Dominique Gauvin, Eric Troncy
Affiliations

Brachystemma calycinum D. Don Effectively Reduces the Locomotor Disability in Dogs with Naturally Occurring Osteoarthritis: A Randomized Placebo-Controlled Trial

Maxim Moreau et al. Evid Based Complement Alternat Med. 2012.

Abstract

Objective. The aim of this randomized placebo-controlled trial was to evaluate the beneficial effect of a whole plant extract of Brachystemma calycinum D. Don (BCD) in naturally occurring osteoarthritis (OA) in dogs. Methods. Dogs had stifle/hip OA and poor limb loading based on the peak of the vertically oriented ground reaction force (PVF) measured using a force platform. At baseline, PVF and case-specific outcome measure of disability (CSOM) were recorded. Dogs (16 per group) were then assigned to receive BCD (200 mg/kg/day) or a placebo. The PVF was measured at week (W) 3 and W6. Locomotor activity was recorded throughout the study duration using collar-mounted accelerometer, and CSOM was assessed biweekly by the owner. Results. BCD-treated dogs had higher PVF at W3 and W6 when compared to Baseline (P < 0.001) and at W6 when compared to placebo-treated dogs (P = 0.040). Higher daily duration (P = 0.024) and intensity (P = 0.012) of locomotor activity were observed in BCD-treated dogs compared to baseline. No significant change was observed in either group for CSOM. Conclusions. Treatment with BCD improved the limb impairment and enhanced the locomotor activity in dogs afflicted by naturally-occurring OA. Those preclinical findings provide interesting and new information about the potential of BCD as an OA therapeutic.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of the study enrolment, randomization, followup, and analysis.
Figure 2
Figure 2
Mean (standard deviation) peak vertical force recorded in dogs having received either Brachystemma calycinum D. Don (BCD) or a placebo. Values are expressed as percentage of body weight. *Significantly different compared to placebo-treated dogs. £Significantly different compared to baseline.
Figure 3
Figure 3
Individual changes in peak vertical force after 6 weeks of treatment with Brachystemma calycinum D. Don (BCD) or a placebo. Changes were the difference between Week 6 versus baseline. *Incomplete data were managed using last data carried forward method. Grey zone represent negative change (i.e., worsening).
Figure 4
Figure 4
Temporal evolution of the locomotor activity recording over a 6-week period (42 days) in dogs receiving either treatment with Brachystemma calycinum D. Don (BCD) or a placebo. Data are the daily duration of active period and are expressed as mean (standard deviation). Periods were baseline (day −5 to day 0, not shown), first period (day 17 to day 21), and the second period (day 38 to day 42). At the second period, BCD-treated dogs had significantly higher daily duration of active period (P = 0.024) when compared to baseline.
Figure 5
Figure 5
Temporal evolution of the case-specific outcome measures of disability (CSOM) over a 6-week period in dogs receiving either treatment with Brachystemma calycinum D. Don (BCD) or a placebo. Data are expressed as mean (standard deviation). Periods were baseline (day 0), first period (day 3 to day 21), and the second period (day 24 to day 42).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Poole R, Blake S, Buschmann M, et al. Recommendations for the use of preclinical models in the study and treatment of osteoarthritis. Osteoarthritis and Cartilage. 2010;18(supplement 3):S10–S16. - PubMed
    1. Johnston SA, Budsberg SC. Nonsteroidal anti-inflammatory drugs and corticosteroids for the management of canine osteoarthritis. Veterinary Clinics of North America. Small Animal Practice. 1997;27(4):841–862. - PubMed
    1. McLaughlin RM. Hind limb lameness in the young patient. Veterinary Clinics of North America. Small Animal Practice. 2001;31(1):101–123. - PubMed
    1. Roush JK. Hind limb lameness in the mature dog. Veterinary Clinics of North America. Small Animal Practice. 2001;31(1):125–141. - PubMed
    1. Cook JL. Cranial cruciate ligament disease in dogs: biology versus biomechanics. Veterinary Surgery. 2010;39(3):270–277. - PubMed

LinkOut - more resources